Jardiance vs Lantus: Cost and Access Head-to-Head

How Each Drug Works and Why the Mechanism Matters

Jardiance and Lantus lower blood glucose by entirely different pathways. Understanding those pathways predicts their side effect profiles, hypoglycemia risk, and the situations where one clearly outperforms the other.

Empagliflozin: Glucose Excretion Through the Kidney

Empagliflozin blocks sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, causing the kidney to excrete approximately 70 to 90 grams of glucose per day in the urine [1]. This lowers fasting and postprandial glucose without triggering insulin release, which is why hypoglycemia is rare when the drug is used without concomitant insulin or sulfonylurea. Empagliflozin also produces modest blood pressure reduction (3 to 5 mmHg systolic) and consistent weight loss of 2 to 3 kg at 26 weeks [2].

The renal mechanism has a ceiling. Empagliflozin requires an estimated glomerular filtration rate (eGFR) of at least 20 mL/min/1.73 m² for glycemic benefit under the current FDA label, and glucose-lowering efficacy diminishes substantially once eGFR falls below 45 [3].

Insulin Glargine: Replacing the Missing Basal Insulin Signal

Lantus is a long-acting insulin analog engineered to precipitate at physiologic pH after subcutaneous injection, producing a depot that dissolves slowly and provides roughly 24 hours of relatively peakless basal coverage [4]. It directly replaces the basal insulin secretion that beta-cell failure has eliminated. Because it can be titrated to any glucose target regardless of renal function, Lantus works in patients with eGFR values where SGLT2 inhibitors lose glycemic potency.

The tradeoff is a dose-dependent risk of hypoglycemia. In ORIGIN (N=12,537), patients randomized to insulin glargine experienced 1.00 episode of confirmed hypoglycemia per patient-year versus 0.31 in the standard-care group (P<0.001) [5].

EMPA-REG OUTCOME vs ORIGIN: What the Trial Data Actually Show

No direct head-to-head randomized trial comparing empagliflozin to insulin glargine for cardiovascular or glycemic outcomes has been published. The two key trials addressed different questions with different populations. Interpreting them side by side requires caution.

EMPA-REG OUTCOME (2015)

EMPA-REG OUTCOME enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease [6]. Participants were randomized to empagliflozin 10 mg, empagliflozin 25 mg, or placebo, on top of standard care. At a median follow-up of 3.1 years, empagliflozin reduced the primary composite outcome (CV death, non-fatal MI, non-fatal stroke) by 14% (HR 0.86, 95% CI 0.74 to 0.99, P<0.001 for noninferiority; P=0.04 for superiority) [6]. Cardiovascular death specifically fell by 38% (HR 0.62, 95% CI 0.49 to 0.77, P<0.001) [6].

Hospitalization for heart failure was reduced by 35% (HR 0.65, 95% CI 0.50 to 0.85, P=0.002) [6]. These findings drove the 2023 and 2024 American Diabetes Association Standards of Care to recommend SGLT2 inhibitors with proven cardiovascular benefit as preferred add-on therapy in patients with established atherosclerotic cardiovascular disease or heart failure, independent of A1C [7].

The ADA 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended to reduce cardiovascular events" [7].

ORIGIN (2012)

ORIGIN enrolled 12,537 adults with dysglycemia (impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes) at high cardiovascular risk [5]. Participants were randomized to insulin glargine (titrated to fasting glucose <95 mg/dL) or standard care. After a median follow-up of 6.2 years, insulin glargine showed a neutral effect on the primary composite CV outcome (HR 1.02, 95% CI 0.94 to 1.11) [5].

The ORIGIN investigators concluded that early basal insulin in dysglycemia did not increase or decrease cardiovascular events. The trial was not powered to show superiority, and the population (earlier-stage glucose dysregulation) differs from the established-CVD cohort in EMPA-REG OUTCOME.

Taken together: empagliflozin has strong trial evidence for CV mortality reduction in high-risk T2D; insulin glargine has neutral CV safety evidence but no proven CV mortality benefit. These data inform guideline positioning, not a direct efficacy comparison.

A1C Lowering: How Much Glucose Control Does Each Drug Deliver?

Empagliflozin A1C Reduction

In the pooled phase 3 program, empagliflozin 10 mg reduced A1C by approximately 0.66 to 0.78 percentage points from baseline versus placebo at 24 weeks in patients with baseline A1C around 8.0% [2]. The glucose-lowering effect is modest relative to basal insulin and depends on adequate renal function.

Insulin Glargine A1C Reduction

Basal insulin titrated to target produces A1C reductions of 1.5 to 2.5 percentage points in most trials, making it substantially more potent for glucose lowering than any oral agent [8]. When A1C exceeds 10% or when patients are symptomatic from hyperglycemia, guidelines recommend initiating insulin rather than cycling through oral agents [7].

The practical rule: if the primary goal is glycemic control with a very high starting A1C, basal insulin reaches target faster. If the primary goal is cardiovascular risk reduction in a patient already near A1C target, empagliflozin adds proven benefit that insulin glargine does not.

Cost Comparison: Cash Price, Insurance, and Assistance Programs

Cost is frequently the deciding factor in medication selection, and the two drugs occupy very different price tiers.

Jardiance Cash and Insurance Cost

The average retail cash price of Jardiance (empagliflozin) 10 mg or 25 mg runs $550 to $650 per 30-tablet supply at major U.S. Pharmacies as of mid-2025. No generic empagliflozin was available in the United States as of this writing; the Jardiance patent is not expected to face generic entry until approximately 2025 to 2026 in some markets [9].

Boehringer Ingelheim and Eli Lilly offer the Jardiance Savings Card, which reduces out-of-pocket cost to as low as $10 per month for commercially insured patients who qualify. Medicare Part D patients do not qualify for manufacturer coupons under federal law, and many Medicare plans place Jardiance on Tier 3 or Tier 4, resulting in monthly copays of $50 to $150 depending on the plan.

Lantus and Insulin Glargine Biosimilar Cost

Brand-name Lantus (Sanofi) retails at approximately $150 to $320 per 10 mL vial or $270 to $400 per package of five SoloSTAR pens, depending on pharmacy and negotiated price. However, three FDA-approved biosimilar insulin glargines have significantly changed the access field [10].

Semglee (Viatris) received the first FDA designation as an interchangeable biosimilar to Lantus in July 2021 [10]. Basaglar (Eli Lilly) and Rezvoglar are also available. Walmart's ReliOn insulin glargine (relabeled Semglee) is available over the counter for approximately $35 per vial without a prescription, representing the lowest available cash price for basal insulin glargine in the United States [11].

The $35 cap on insulin cost-sharing for Medicare Part D beneficiaries, enacted under the Inflation Reduction Act of 2022, applies to all covered insulins including insulin glargine biosimilars [12].

A Practical Cost-Access Decision Framework

The following framework captures how cost and access interact with clinical profile:

Patient has commercial insurance, established CVD, A1C 7.5 to 9.5%: Jardiance is likely Tier 2 to Tier 3 on formulary. Manufacturer savings card reduces cost to $10/month. EMPA-REG data support this choice on outcomes grounds. Start here if eGFR is above 45.

Patient is Medicare, established CVD, A1C 7.5 to 9.5%: Jardiance manufacturer coupon is not available. Check plan formulary tier. If Tier 4 or non-formulary, cost burden may be $100 to $200/month. Insulin glargine biosimilar is capped at $35/month under Part D. If cardiovascular benefit is the clinical priority, a prior authorization appeal citing EMPA-REG data may be warranted.

Patient has A1C above 10%, symptomatic hyperglycemia, any insurance status: Insulin glargine biosimilar at $35/vial at Walmart provides immediate, potent glucose control. This is the most cost-accessible choice and the most clinically appropriate one for severe hyperglycemia.

Patient is uninsured, A1C 7.5 to 9.0%, no CVD: Walmart ReliOn insulin glargine at $35/vial is the most accessible option. Empagliflozin without insurance at $600/month is unlikely to be sustainable.

Cardiovascular and Renal Outcomes: Who Gets the Most Benefit

Heart Failure and Empagliflozin

The 35% reduction in heart failure hospitalization seen in EMPA-REG OUTCOME [6] has since been confirmed and extended. The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced the composite of CV death or heart failure hospitalization by 25% (HR 0.75, 95% CI 0.65 to 0.86, P<0.001) in patients with heart failure with reduced ejection fraction, including those without type 2 diabetes [13]. The FDA approved empagliflozin for heart failure treatment independent of diabetes status in 2021 [14].

Insulin glargine has no approved heart failure indication and no trial data showing benefit on heart failure hospitalization.

Renal Protection

The EMPA-KIDNEY trial (N=6,609) demonstrated that empagliflozin 10 mg reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) in patients with chronic kidney disease, including those with eGFR as low as 20 mL/min/1.73 m² [15]. This trial led to an expanded FDA indication for empagliflozin in chronic kidney disease in 2023 [14].

Insulin glargine does not carry an approved renal-protective indication, though adequate glycemic control with any agent reduces the risk of diabetic nephropathy progression over time [16].

Safety Comparison: What Each Drug Can Do to Patients

Hypoglycemia

Empagliflozin monotherapy carries a very low hypoglycemia risk because it does not stimulate insulin secretion. In EMPA-REG OUTCOME, confirmed hypoglycemic events occurred in 8.3% of empagliflozin patients versus 7.9% of placebo patients, with most events attributable to background sulfonylurea or insulin use [6].

Insulin glargine carries a meaningful hypoglycemia burden. Confirmed hypoglycemia rates in ORIGIN reached 1.00 event per patient-year in the glargine arm [5]. Nocturnal hypoglycemia is a particular concern in elderly patients and those with hypoglycemia unawareness [17].

Genital Mycotic Infections and DKA

SGLT2 inhibitors increase the risk of genital mycotic infections (candidal vulvovaginitis and balanitis) by approximately threefold compared with placebo [2]. Euglycemic diabetic ketoacidosis (DKA), though rare at approximately 0.1 to 0.2% per year, is a serious adverse event requiring patient education about sick-day management and carbohydrate restriction [18].

Insulin glargine is not associated with genital infections or euglycemic DKA, though overdose or missed meal timing can cause severe hypoglycemia.

Weight Effects

Empagliflozin produces a net weight reduction of 2 to 3 kg at 26 weeks, sustained over longer follow-up [2]. Insulin glargine typically causes weight gain of 1.5 to 3 kg over 6 to 12 months, which can complicate metabolic management in obese patients [8].

Guideline Positioning: Where Each Drug Fits in T2D Treatment Algorithms

The 2024 ADA Standards of Medical Care in Diabetes position these agents in distinct but potentially complementary roles [7].

ADA 2024 on SGLT2 Inhibitors

For patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, SGLT2 inhibitors with proven benefit are recommended as part of the glucose-lowering regimen independent of A1C or metformin use. Empagliflozin is one of the agents named with trial-level evidence [7].

The ADA 2024 Standards state: "In patients with type 2 diabetes and heart failure, an SGLT2 inhibitor with proven benefit is recommended to reduce the risk of heart failure hospitalization and cardiovascular death" [7].

ADA 2024 on Basal Insulin

Basal insulin initiation is recommended when A1C remains above individualized targets despite oral agents and injectable non-insulin therapies, or when A1C exceeds 10 to 11% at diagnosis. The ADA recommends starting at 10 units per day or 0.1 to 0.2 units per kg per day and titrating by 2 units every 3 days until fasting glucose reaches target [7].

The two drugs are not alternatives in a patient with severe hyperglycemia requiring insulin. They become alternatives only in patients who are insulin-naive, near glycemic target, and choosing between an SGLT2 inhibitor for cardiovascular protection versus basal insulin for additional glucose lowering.

Switching Between Jardiance and Lantus: Clinical Considerations

Switching from one drug to the other is clinically reasonable in certain situations, and the direction of the switch determines the risk profile.

Switching From Lantus to Jardiance

A patient who has achieved reasonable glycemic control on basal insulin but has been diagnosed with heart failure or established CVD may benefit from adding empagliflozin rather than substituting it. Abrupt discontinuation of basal insulin in a patient who requires it for glycemic control risks hyperglycemia. The appropriate sequence is to add empagliflozin, monitor fasting glucose, and reduce the insulin glargine dose by 10 to 20% only if hypoglycemia develops [7].

Substituting empagliflozin for insulin glargine outright is appropriate only if the patient's A1C is at or near target, beta-cell function is sufficient for oral therapy, and insulin is being used primarily for glucose lowering rather than survival (as in type 1 diabetes). Jardiance is not indicated in type 1 diabetes [14].

Switching From Jardiance to Lantus

Adding basal insulin to a regimen that includes empagliflozin is straightforward. The combination is used in clinical practice and was studied in the EASE program [19]. A clinician starting insulin glargine in a patient on empagliflozin should educate the patient about the additive hypoglycemia risk when the sulfonylurea or prandial insulin is added, and should note that SGLT2 inhibitor-associated euglycemic DKA risk persists [18].

Access Barriers Beyond Price: Prior Authorization, Formulary Tier, and Step Therapy

Jardiance faces significant prior authorization requirements at many payers. A 2022 analysis found that SGLT2 inhibitors required prior authorization at 67% of commercial plans and 74% of Medicare Advantage plans, with step therapy requirements demanding proof of metformin failure at 58% of plans [20].

Insulin glargine biosimilars face minimal prior authorization barriers. ReliOn glargine at Walmart requires no prescription, which removes even the prescriber-access hurdle for uninsured or underinsured patients [11].

For patients in states with insulin cost-sharing caps, the out-of-pocket maximum for insulin is capped at $35 per 30-day supply under laws enacted in approximately 25 states as of 2024 [21]. Empagliflozin is not classified as insulin and does not qualify for these caps.

The net access picture: insulin glargine biosimilar is the most accessible glucose-lowering agent by cash price and formulary tier. Jardiance requires commercial insurance or a willingness to pay $550 to $650 per month without assistance, except for Medicare Part D patients whose plans cover it at lower tiers.

Combining Both Drugs: Is There a Synergistic Clinical Rationale?

Using both agents together is clinically rational in select patients. A patient with type 2 diabetes, established heart failure, and an A1C above 9% on oral therapy may benefit from insulin glargine for glycemic control and empagliflozin for heart failure hospitalization reduction simultaneously. The EASE-3 trial (N=241) showed that adding empagliflozin to insulin-treated patients produced an A1C reduction of 0.94 percentage points versus 0.26 for placebo at 26 weeks, with a 2.2 kg weight loss and a 21% reduction in total daily insulin dose [19].

This combination also allows insulin dose reduction, which directly reduces hypoglycemia risk and attenuates insulin-associated weight gain. Clinicians should reduce basal insulin by 10 to 20% when adding empagliflozin to minimize hypoglycemia [7].